Exhibit 107

Calculation of Filing Fee Tables

Form S-3

(Form Type)

BioCryst Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

Security Type

Security Class Title

Fee Calculation or Carry Forward Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Carry Forward Form Type

Carry Forward File Number

Carry Forward Initial Effective Date

Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward

Newly Registered Securities

Equity

Common Stock, par value $0.01 (1)

Rule 456(b) and Rule 457(r) (2)

(2)

(2)

(2)

(3)

(3)

Equity

Preferred Stock, par value $0.01 (1)

Rule 456(b) and Rule 457(r) (2)

(2)

(2)

(2)

(3)

(3)

Fees to be Paid

Other

Depositary Shares (1)

Rule 456(b) and Rule 457(r) (2)

(2)

(2)

(2)

(3)

(3)

Other

Purchase Contracts (1)

Rule 456(b) and Rule 457(r) (2)

(2)

(2)

(2)

(3)

(3)

Other

Warrants (1)

Rule 456(b) and Rule 457(r) (2)

(2)

(2)

(2)

(3)

(3)

Debt

Debt Securities (1)

Rule 456(b) and Rule 457(r) (2)

(2)

(2)

(2)

(3)

(3)

Other

Units (1)

Rule 456(b) and Rule 457(r) (2)

(2)

(2)

(2)

(3)

(3)

Carry Forward Securities

Carry Forward Securities

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Total Offering Amounts

N/A

N/A

Total Fees Previously Paid

N/A

Total Fee Offsets

N/A

Net Fee Due

N/A

(1) Any securities registered hereunder may be sold separately or as units with other securities registered hereunder.

(2) Omitted pursuant to Instruction 2.A.iii.c. to Item 16(b) of Form S-3. An indeterminate aggregate offering price or number of securities of each identified class is being registered as may from time to time be offered at indeterminate prices. Includes such indeterminate amounts of securities as may be issued upon exercise, conversion or exchange of, or pursuant to anti-dilution adjustments with respect to, any securities that provide for that issuance or adjustment. Also includes such indeterminate amount as may be issued in units. Separate consideration may or may not be received for securities that are issuable on exercise, conversion or exchange of, or pursuant to anti-dilution adjustments with respect to, any other securities.

(3) The registrant is deferring payment of the registration fee pursuant to Rule 456(b) under the Securities Act of 1933, as amended (the “Securities Act”) and is excluding this information in reliance on Rule 456(b) and Rule 457(r) under the Securities Act. Any registration fees will be paid subsequently on a pay-as-you-go basis.